β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy

The immune context of tumors has significant prognostic value and is predictive of responsiveness to several forms of therapy, including immunotherapy. We report here that CD8(+) T-cell frequency and functional orientation within the tumor microenvironment is regulated by beta(2)-adrenergic receptor (beta-AR) signaling in host immune cells. We used three strategies-physiologic (manipulation of ambient thermal environment), pharmacologic (beta-blockers), and genetic (beta(2)-AR knockout mice) to reduce adrenergic stress signaling in two widely studied preclinical mouse tumor models. Reducing beta-AR signaling facilitated conversion of tumors to an immunologically active tumor microenvironment with increased intratumoral frequency of CD8(+) T cells with an effector phenotype and decreased expression of programmed death receptor-1 (PD-1), in addition to an elevated effector CD8(+) T-cell to CD4(+) regulatory T-cell ratio (IFN gamma(+) CD8(+): Treg). Moreover, this conversion significantly increased the efficacy of anti-PD-1 checkpoint blockade. These data highlight the potential of adrenergic stress and norepinephrine-driven beta-AR signaling to regulate the immune status of the tumor microenvironment and support the strategic use of clinically available beta-blockers in patients to improve responses to immunotherapy. (C) 2017 AACR.